Patents by Inventor Chris J. JANSE

Chris J. JANSE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genetic attenuation of plasmodium by B9 gene disruption
    Patent number: 9931389
    Abstract: Disclosed herein are mutant Plasmodium-species parasites that are genetically attenuated (GAP). They retain the ability to infect a host and invade host hepatocytes but subsequently their development is completely arrested within the liver stage of Plasmodium development and the parasites do not reach the blood stage of development. Vaccines and pharmaceutical compositions comprising genetically attenuated Plasmodium sporozoites as well as methods of using the same are likewise provided.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: April 3, 2018
    Assignees: SANARIA INC., ACADEMISCH ZIEKENHUIS LEIDEN, STICHTING KATHOLIEKE UNIVERSTEIT
    Inventors: Chris J. Janse, Takeshi Annoura, Shahid M. Khan, Ben Van Schaijk, Ivo Hj Ploemen, Martijn W. Vos, Robert Sauerwein
  • Genetic attenuation of by B9 gene disruption
    Patent number: 9764016
    Abstract: Disclosed herein are mutant Plasmodium-species parasites that are genetically attenuated (GAP). They retain the ability to infect a host and invade host hepatocytes but subsequently their development is completely arrested within the liver stage of Plasmodium development and the parasites do not reach the blood stage of development. Vaccines and pharmaceutical compositions comprising genetically attenuated Plasmodium sporozoites as well as methods of using the same are likewise provided.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: September 19, 2017
    Inventors: Chris J. Janse, Takeshi Annoura, Shahid M. Khan, Ben Van Schaijk, Ivo H J Ploemen, Martijn W. Vos, Robert Sauerwein
  • Genetic Attenuation of Plasmodium by B9 Gene Disruption
    Publication number: 20170252419
    Abstract: Disclosed herein are mutant Plasmodium-species parasites that are genetically attenuated (GAP). They retain the ability to infect a host and invade host hepatocytes but subsequently their development is completely arrested within the liver stage of Plasmodium development and the parasites do not reach the blood stage of development. Vaccines and pharmaceutical compositions comprising genetically attenuated Plasmodium sporozoites as well as methods of using the same are likewise provided.
    Type: Application
    Filed: March 14, 2017
    Publication date: September 7, 2017
    Inventors: Chris J. JANSE, Takeshi ANNOURA, Shahid M. KHAN, Ben VAN SCHAIJK, Ivo HJ PLOEMEN, Martijn W. VOS, Robert SAUERWEIN
  • Genetic Attenuation of Plasmodium by B9 Gene Disruption
    Publication number: 20150313980
    Abstract: Disclosed herein are mutant Plasmodium-species parasites that are genetically attenuated (GAP). They retain the ability to infect a host and invade host hepatocytes but subsequently their development is completely arrested within the liver stage of Plasmodium development and the parasites do not reach the blood stage of development. Vaccines and pharmaceutical compositions comprising genetically attenuated Plasmodium sporozoites as well as methods of using the same are likewise provided.
    Type: Application
    Filed: January 24, 2014
    Publication date: November 5, 2015
    Inventors: Chris J. JANSE, Takeshi ANNOURA, Shahid M. KHAN, Ben VAN SCHAIJK, Ivo HJ PLOEMEN, Martijn W. VOS, Robert SAUERWEIN